论文部分内容阅读
目的观察瑞舒伐他汀对急性脑梗死患者血浆超敏C反应蛋白(hs CRP)及一氧化氮(NO)水平的影响.方法140例脑梗死急性期患者随机分为两组,常规治疗组70例,给予常规抗血小板聚集、改善循环、营养神经治疗;瑞舒伐他汀治疗组70例,在常规治疗组基础上每晚加服瑞舒伐他汀10 mg,均治疗14 d,观察治疗前后hs CRP,NO的变化情况.结果 1)与常规治疗前比较,瑞舒伐他汀治疗后hs CRP显著下降,差异具有统计学意义(P<0.05);2)各组在治疗14 d后,瑞舒伐他汀治疗组NO较常规组明显升高,差异具有统计学意义(P<0.05);3)治疗前hs CRP与神经功能缺损评分呈正相关(r=0.397,P=0.001);治疗前NO与神经功能缺损评分呈显著负相关(r=-0.365,P=0.006).结论血浆hs CRP,NO与急性脑梗死的严重程度密切相关,瑞舒伐他汀能明显降低急性脑梗死患者血浆hs CRP水平,升高NO水平,瑞舒伐他汀可作为治疗急性脑梗死早期应用药物.
Objective To observe the effect of rosuvastatin on plasma hs-CRP and NO levels in patients with acute cerebral infarction.Methods 140 patients with acute cerebral infarction were randomly divided into two groups: the conventional treatment group 70 Cases, given conventional anti-platelet aggregation, improve circulation, nutrition and nerve treatment; rosuvastatin treatment group of 70 patients in the conventional treatment group based on the night plus service rosuvastatin 10 mg, were treated for 14 days, before and after treatment hs CRP and NO.Results1) Compared with pre-treatment, hs CRP of rosuvastatin significantly decreased after treatment (P <0.05); 2) After 14 days of treatment, Compared with normal group, the NO in statin group was significantly higher than that in routine group (P <0.05); 3) There was a positive correlation between CRP and neurological deficit score before treatment (r = 0.397, P = 0.001) (R = -0.365, P = 0.006) .Conclusion Plasma hs-CRP and NO are closely related to the severity of acute cerebral infarction. Rosuvastatin can significantly reduce the plasma hs-CRP levels in patients with acute cerebral infarction , Increase the level of NO, rosuvastatin can be used as early treatment of acute cerebral infarction drug.